Get the Stockscreener App
32.17
3.08%
0.96
After Hours:
32.49
0.32
+0.99%
Alkermes Plc stock is traded at $32.17, with a volume of 1.68M.
It is up +3.08% in the last 24 hours and up +19.28% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$31.21
Open:
$31.39
24h Volume:
1.68M
Relative Volume:
0.88
Market Cap:
$5.31B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
16.50
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
+3.81%
1M Performance:
+19.28%
6M Performance:
+19.15%
1Y Performance:
+11.28%
1-Day Range:
$31.25
$32.31
1-Week Range:
$30.70
$32.31
52-Week Range:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
32.17 | 5.15B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
142.26 | 62.54B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 43.30B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.08 | 40.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.02 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
440.06 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-26-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Order flow analysis tools used on Alkermes plcDay Trade & AI Enhanced Execution Alerts - newser.com
Why Alkermes plc stock appeals to analystsTrade Analysis Summary & Comprehensive Market Scan Insights - newser.com
Is now a turning point for Alkermes plcQuarterly Portfolio Summary & Trade Opportunity Analysis - newser.com
Full technical analysis of Alkermes plc stock2025 Volume Leaders & Long-Term Capital Growth Ideas - newser.com
What technical models suggest about Alkermes plc’s comebackBear Alert & Verified Trade Idea Suggestions - newser.com
Is Alkermes plc a good long term investmentDouble Top/Bottom Patterns & Identify Safe Investments - earlytimes.in
Can Alkermes plc stock deliver strong Q4 earningsMarket Risk Summary & Fast Moving Market Watchlists - newser.com
Is Alkermes plc (8AK) stock cheap vs fundamentalsShort Setup & Fast Gain Stock Trading Tips - newser.com
Historical volatility pattern of Alkermes plc visualizedJuly 2025 Decliners & High Conviction Buy Zone Picks - newser.com
Ranking Alkermes plc among high performing stocks via toolsJuly 2025 Movers & Comprehensive Market Scan Insights - newser.com
Real time breakdown of Alkermes plc stock performance2025 Pullback Review & Advanced Technical Analysis Signals - newser.com
Alkermes Plc Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
How cyclical is Alkermes plc (8AK) stock compared to rivalsEarnings Overview Report & Fast Gaining Stock Strategy Reports - newser.com
Pattern recognition hints at Alkermes plc upside2025 Stock Rankings & Daily Market Momentum Tracking - newser.com
Will Alkermes plc (8AK) stock hit Wall Street targetsProduct Launch & AI Powered Market Entry Ideas - newser.com
Is Alkermes Plc (NASDAQ:ALKS) Trading At A 43% Discount? - 富途牛牛
Alkermes upgraded at RBC Capital Markets ahead of key catalyst - MSN
RBC Lifts Price Target on Alkermes to $45 From $44, Keeps Outperform Rating - MarketScreener
Do Options Traders Know Something About Alkermes Stock We Don't? - Yahoo Finance
Robeco Institutional Asset Management B.V. Buys 36,467 Shares of Alkermes plc $ALKS - MarketBeat
Substance Abuse Treatment Market Size, Growth Analysis 2031 - openPR.com
Is Alkermes plc (8AK) stock at risk of policy regulationGold Moves & Daily Entry Point Alerts - newser.com
Is Alkermes plc reversing from oversold territoryTrade Risk Assessment & Reliable Breakout Stock Forecasts - newser.com
Technical analysis overview for Alkermes plc stockMarket Weekly Review & Fast Exit/Entry Strategy Plans - newser.com
Alkermes Plc Experiences Evaluation Revision Amidst Mixed Market Signals and Performance Trends - Markets Mojo
Alkermes sued over alleged scheme to block generic Vivitrol - Reuters
Will Alkermes plc (8AK) stock benefit from Fed rate cuts2025 Market Overview & Comprehensive Market Scan Insights - newser.com
What candlestick patterns are forming on Alkermes plcJuly 2025 Patterns & Fast Gain Stock Trading Tips - newser.com
Alkermes Plc Hits Day High with Strong 10.58% Intraday Surge - Markets Mojo
Alkermes (ALKS) Added to Wells Fargo's Tactical Ideas List - GuruFocus
What analysts say about Alkermes plc 8AK stockPrice-to-Earnings Ratio Insights & Budget Friendly Capital Growth - earlytimes.in
What drives Alkermes plc stock priceMarket Breadth Indicators & Explosive Profit Trading - earlytimes.in
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alkermes Plc Stock (ALKS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nichols Christian Todd | SVP, Chief Commercial Officer |
Jun 10 '25 |
Sale |
31.09 |
3,334 |
103,654 |
86,208 |
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):